Institution
McMaster University
Education•Hamilton, Ontario, Canada•
About: McMaster University is a education organization based out in Hamilton, Ontario, Canada. It is known for research contribution in the topics: Population & Health care. The organization has 41361 authors who have published 101269 publications receiving 4251422 citations.
Papers published on a yearly basis
Papers
More filters
••
TL;DR: The combination of candesartan and enalapril was more beneficial for preventing left ventricular remodeling than either candeartan or en alapril alone and was as effective, safe, and tolerable as enalAPril.
Abstract: Background—We investigated the effects of candesartan (an angiotensin II antagonist) alone, enalapril alone, and their combination on exercise tolerance, ventricular function, quality of life (QOL)...
904 citations
••
TL;DR: Comparisons of S proteins of SARS‐CoV isolated during the 2002–2003 SARS outbreak and during the much less severe 2003–2004 outbreak, and from palm civets, provide insight into the severity of the 2002‐ 2003 SARS epidemic.
Abstract: Human angiotensin-converting enzyme 2 (ACE2) is a functional receptor for SARS coronavirus (SARS-CoV) Here we identify the SARS-CoV spike (S)-protein-binding site on ACE2 We also compare S proteins of SARS-CoV isolated during the 2002-2003 SARS outbreak and during the much less severe 2003-2004 outbreak, and from palm civets, a possible source of SARS-CoV found in humans All three S proteins bound to and utilized palm-civet ACE2 efficiently, but the latter two S proteins utilized human ACE2 markedly less efficiently than did the S protein obtained during the earlier human outbreak The lower affinity of these S proteins could be complemented by altering specific residues within the S-protein-binding site of human ACE2 to those of civet ACE2, or by altering S-protein residues 479 and 487 to residues conserved during the 2002-2003 outbreak Collectively, these data describe molecular interactions important to the adaptation of SARS-CoV to human cells, and provide insight into the severity of the 2002-2003 SARS epidemic
903 citations
••
TL;DR: This study examined factors associated with ventilator-associated pneumonia and explored baseline and time-dependent characteristics, including measures of illness severity, factors relating to mechanical ventilation, variables in the gastropulmonary route of infection, and drug exposure.
Abstract: Background: Understanding the risk factors for ventilator-associated pneumonia can help to assess prognosis and devise and test preventive strategies Objective: To examine the baseline and time-de
903 citations
••
McMaster University1, University of British Columbia2, Queen's University3, University of Toronto4, Peter MacCallum Cancer Centre5, Université de Sherbrooke6, Medical Research Council7, Ohio State University8, Université de Montréal9, Laval University10, Princess Margaret Cancer Centre11, Cross Cancer Institute12
TL;DR: This study randomly assigned women with node-positive or high-risk node-negative breast cancer who were treated with breast-conserving surgery and adjuvant systemic therapy to undergo whole-breast irradiation plus regional nodal irradiation (including internal mammary, supraclavicular, and axillary lymph nodes).
Abstract: BackgroundMost women with breast cancer who undergo breast-conserving surgery receive whole-breast irradiation. We examined whether the addition of regional nodal irradiation to whole-breast irradiation improved outcomes. MethodsWe randomly assigned women with node-positive or high-risk node-negative breast cancer who were treated with breast-conserving surgery and adjuvant systemic therapy to undergo either whole-breast irradiation plus regional nodal irradiation (including internal mammary, supraclavicular, and axillary lymph nodes) (nodal-irradiation group) or whole-breast irradiation alone (control group). The primary outcome was overall survival. Secondary outcomes were disease-free survival, isolated locoregional disease-free survival, and distant disease-free survival. ResultsBetween March 2000 and February 2007, a total of 1832 women were assigned to the nodal-irradiation group or the control group (916 women in each group). The median follow-up was 9.5 years. At the 10-year follow-up, there was n...
903 citations
••
TL;DR: Rivaroxaban was associated with relatively low VTE recurrence but higher CRNMB compared with dalteparin, and safety was assessed by major bleeding and clinically relevant nonmajor bleeding (CRNMB).
Abstract: PurposeVenous thromboembolism (VTE) is common in patients with cancer. Long-term daily subcutaneous low molecular weight heparin has been standard treatment for such patients. The purpose of this study was to assess if an oral factor Xa inhibitor, rivaroxaban, would offer an alternative treatment for VTE in patients with cancer.Patient and MethodsIn this multicenter, randomized, open-label, pilot trial in the United Kingdom, patients with active cancer who had symptomatic pulmonary embolism (PE), incidental PE, or symptomatic lower-extremity proximal deep vein thrombosis (DVT) were recruited. Allocation was to dalteparin (200 IU/kg daily during month 1, then 150 IU/kg daily for months 2-6) or rivaroxaban (15 mg twice daily for 3 weeks, then 20 mg once daily for a total of 6 months). The primary outcome was VTE recurrence over 6 months. Safety was assessed by major bleeding and clinically relevant nonmajor bleeding (CRNMB). A sample size of 400 patients would provide estimates of VTE recurrence to within ±...
902 citations
Authors
Showing all 41721 results
Name | H-index | Papers | Citations |
---|---|---|---|
Salim Yusuf | 231 | 1439 | 252912 |
Gordon H. Guyatt | 231 | 1620 | 228631 |
Simon D. M. White | 189 | 795 | 231645 |
George Efstathiou | 187 | 637 | 156228 |
Stuart H. Orkin | 186 | 715 | 112182 |
Terrie E. Moffitt | 182 | 594 | 150609 |
John J.V. McMurray | 178 | 1389 | 184502 |
Jasvinder A. Singh | 176 | 2382 | 223370 |
Deborah J. Cook | 173 | 907 | 148928 |
Andrew P. McMahon | 162 | 415 | 90650 |
Jack Hirsh | 146 | 734 | 86332 |
Holger J. Schünemann | 141 | 810 | 113169 |
John A. Peacock | 140 | 565 | 125416 |
David Price | 138 | 1687 | 93535 |
Graeme J. Hankey | 137 | 844 | 143373 |